Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY28.70
+3.46 (+13.71%)
CN SHZ Healthcare Biotechnology
Address
Zhengding County High-tech Ind Dev Zone 50800
Shijiazhuang, CN
Shijiazhuang, CN
CEO
Xiaodong Gao
Website
heparin.cn
IPO
2011-08-19
ISIN CNE1000016C2
Description
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY28.70
+3.46 (+13.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26M
Beta
0.29
Float Shares
452.13M
Free Float %
49.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.88% | +1.35% | -0.27% | -11.58% | -33.63% | -33.57% | +10.32% | +694.80% | +455.18% | +428.17% | +916.01% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
28.70
Ratings Trend (MoM)
67% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.39
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-15.1% Q1'26: -1.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-44.4% Q1'26: +56.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-31.6% Q1'26: -3.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-29.6% Q1'26: +10.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-8.8% ★ Q1'26: +2.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.7% ★ Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-10.08× Q1'26: 21.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
915.99M
est: 1.01B (-9.5%)
|
1.12B
est: 1.11B (+0.4%)
|
1.42B
est: 1.11B (+27.5%)
|
1.65B
est: 1.26B (+31.5%)
|
2.07B
est: 1.52B (+36.0%)
|
2.36B
est: 1.81B (+30.9%)
|
2.97B
est: 2.55B (+16.6%)
|
2.34B
est: 3.16B (-26.2%)
|
1.41B
est: 4.00B (-64.7%)
|
875.13M
est: 1.11B (-21.4%)
|
1.26B
1.26B – 1.26B
+12.8% YoY
|
1.52B
1.52B – 1.52B
+21.2% YoY
|
1.81B
1.81B – 1.81B
+18.6% YoY
|
2.55B
2.55B – 2.55B
+41.0% YoY
|
3.16B
3.16B – 3.16B
+24.3% YoY
|
4.00B
4.00B – 4.00B
+26.3% YoY
|
| EBITDA |
235.46M
est: -98.09M (+340.0%)
|
262.57M
est: -107.98M (+343.2%)
|
303.71M
est: -107.98M (+381.3%)
|
325.98M
est: -121.78M (+367.7%)
|
357.44M
est: -147.65M (+342.1%)
|
424.06M
est: -175.04M (+342.3%)
|
379.86M
est: -246.79M (+253.9%)
|
164.93M
est: -306.69M (+153.8%)
|
-1.07B
est: -387.43M (-176.3%)
|
-188.91M
est: -196.05M (+3.6%)
|
-221.11M
-221.11M – -221.11M
-12.8% YoY
|
-268.06M
-268.06M – -268.06M
-21.2% YoY
|
-317.79M
-317.79M – -317.79M
-18.6% YoY
|
-448.05M
-448.05M – -448.05M
-41.0% YoY
|
-556.81M
-556.81M – -556.81M
-24.3% YoY
|
-703.41M
-703.41M – -703.41M
-26.3% YoY
|
| EBIT |
203.57M
est: -136.37M (+249.3%)
|
225.65M
est: -150.12M (+250.3%)
|
261.60M
est: -150.12M (+274.3%)
|
280.43M
est: -169.30M (+265.6%)
|
305.15M
est: -205.26M (+248.7%)
|
368.78M
est: -243.34M (+251.6%)
|
324.06M
est: -343.08M (+194.5%)
|
107.99M
est: -426.36M (+125.3%)
|
-1.14B
est: -538.61M (-112.6%)
|
-258.98M
est: -250.81M (-3.3%)
|
-282.87M
-282.87M – -282.87M
-12.8% YoY
|
-342.94M
-342.94M – -342.94M
-21.2% YoY
|
-406.56M
-406.56M – -406.56M
-18.6% YoY
|
-573.22M
-573.22M – -573.22M
-41.0% YoY
|
-712.36M
-712.36M – -712.36M
-24.3% YoY
|
-899.90M
-899.90M – -899.90M
-26.3% YoY
|
| Net Income |
156.30M
est: 189.94M (-17.7%)
|
175.49M
est: 184.80M (-5.0%)
|
196.92M
est: 184.80M (+6.6%)
|
139.99M
est: 221.76M (-36.9%)
|
225.29M
est: 286.44M (-21.3%)
|
252.84M
est: 360.36M (-29.8%)
|
233.57M
est: 277.20M (-15.7%)
|
17.51M
est: 369.60M (-95.3%)
|
-1.24B
est: 462.00M (-368.4%)
|
-357.90M
est: 183.54M (-295.0%)
|
220.24M
220.24M – 220.24M
+20.0% YoY
|
284.48M
284.48M – 284.48M
+29.2% YoY
|
357.90M
357.90M – 357.90M
+25.8% YoY
|
275.30M
275.30M – 275.30M
-23.1% YoY
|
367.07M
367.07M – 367.07M
+33.3% YoY
|
458.84M
458.84M – 458.84M
+25.0% YoY
|
| SGA |
399.28M
est: 374.28M (+6.7%)
|
483.10M
est: 412.01M (+17.3%)
|
573.82M
est: 412.01M (+39.3%)
|
775.81M
est: 464.67M (+67.0%)
|
1.05B
est: 563.35M (+85.7%)
|
1.10B
est: 667.87M (+64.4%)
|
1.22B
est: 941.63M (+29.6%)
|
739.69M
est: 1.17B (-36.8%)
|
630.71M
est: 1.48B (-57.3%)
|
84.45M
est: 330.05M (-74.4%)
|
372.24M
372.24M – 372.24M
+12.8% YoY
|
451.28M
451.28M – 451.28M
+21.2% YoY
|
535.01M
535.01M – 535.01M
+18.6% YoY
|
754.31M
754.31M – 754.31M
+41.0% YoY
|
937.41M
937.41M – 937.41M
+24.3% YoY
|
1.18B
1.18B – 1.18B
+26.3% YoY
|
| EPS |
0.18
est: 0.21 (-12.4%)
|
0.20
est: 0.20 (+0.0%)
|
0.21
est: 0.20 (+5.0%)
|
0.15
est: 0.24 (-37.5%)
|
0.24
est: 0.31 (-22.6%)
|
0.28
est: 0.39 (-28.2%)
|
0.25
est: 0.30 (-16.7%)
|
0.02
est: 0.40 (-95.2%)
|
-1.35
est: 0.50 (-370.0%)
|
-0.39
est: 0.20 (-295.0%)
|
0.24
0.24 – 0.24
+20.0% YoY
|
0.31
0.31 – 0.31
+29.2% YoY
|
0.39
0.39 – 0.39
+25.8% YoY
|
0.30
0.30 – 0.30
-23.1% YoY
|
0.40
0.40 – 0.40
+33.3% YoY
|
0.50
0.50 – 0.50
+25.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-242.74M
OE per share TTM
-0.26
Owner's Yield
-0.64%
Maintenance CapEx ratio
534.36%
Maint CapEx / Avg PPE
74.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 83 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.88% | 1.51M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 0.58% | 462.5K | 0.79% |
| 3 | VanEck ChiNext ETF CNXT | 0.26% | 315.2K | 0.65% |
| 4 | iShares MSCI China A UCITS ETF CNYE.MI | 0.05% | 50.1K | 0.45% |
| 5 | iShares MSCI China A UCITS ETF CNYA.L | 0.05% | 1.52M | 0.40% |
| 6 | iShares MSCI China A ETF CNYA | 0.04% | 103.0K | 0.60% |
| 7 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.04% | 59.6K | 0.35% |
| 8 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 31.1K | 0.55% |
| 9 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.03% | 44.9K | 0.35% |
| 10 | Invesco MSCI China All Shares Stock Connect UCITS ETF MCHN.L | 0.02% | 21.4K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-183.7K
Shares Outstanding
919.06M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guohong An | Deputy General Manager | — | female |
| Qing Zhang | Deputy General Manager | — | female |
| Xiaodong Gao | Chairman of the Board & GM | — | male |
| Xiaohua Yue | Deputy GM & Chief Financial Officer | — | female |
| Xnjun Zhang | Deputy General Manager | — | male |
| Yanlu Chang | Deputy General Manager | — | male |
| Yunxia Sun | Deputy GM & Non-Independent Director | — | female |
| Zhang Tao | Deputy General Manager | — | male |
| Zhenggang Qie | Deputy GM & Non-Independent Director | — | male |
| Zhihua Li | Deputy General Manager | — | male |
| Zhongying Liu | Deputy GM & Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300255.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
